Niagen Bioscience, Inc. current report, 02 November 2022

SEC Filing Summary: ChromaDex Corporation (8-K)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on November 2, 2022. The filing serves as a current report to announce the release of the Company's earnings for the quarter ended September 30, 2022, and the availability of a corporate investor presentation. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CDXC.

Key Financial Metrics

The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are referenced but not included in the body of this 8-K document.

Material Changes

No material changes to financial performance or operations are detailed within the text of this filing. The document solely acts as a notification that the Q3 2022 results have been issued.

Guidance, Outlook, and Risks

Management commentary, forward-looking guidance, and risk factors are not explicitly stated in this filing. The Company notes that the information furnished in Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific Q3 2022 revenue, net income, and cash flow figures.
  • Examine Exhibit 99.2 (Investor Presentation) for updated financial guidance and strategic outlook.
  • Verify the Company's liquidity position and debt obligations as detailed in the attached exhibits.
  • Confirm the status of the Interim Chief Financial Officer, Brianna L. Gerber, as the principal financial officer signing the report.